Nasus Pharma (NSRX) Assets (2024 - 2025)
Nasus Pharma's (NSRX) quarterly Assets came in at $5.0 million in Q4 2025, up 597.91% YoY from $717000.0 in Q4 2024, and up 683.1% on a QoQ basis from $639000.0 in Q2 2025.
Nasus Pharma (NSRX) Assets (2024 - 2025) Analysis & Trends
Nasus Pharma (NSRX) has 2 years of Assets data on file, last reported at $5.0 million in Q4 2025.
- Quarterly Assets rose 597.91% year-over-year to $5.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $5.0 million (up 597.91% YoY) and the FY2025 annual result came in at $5.0 million, up 597.91% from the prior year.
- Assets climbed to $5.0 million in Q4 2025, from $639000.0 in the prior quarter.
- In the past five years, Assets ranged from a high of $5.0 million in Q4 2025 to a low of $639000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 653.37 Bn | 632.61 Bn | 17.26 Bn | 201.06 Bn |
| 2 | AbbVie | 470.31 Bn | 463.74 Bn | 12.70 Bn | 135.12 Bn |
| 3 | Merck | 377.07 Bn | 369.93 Bn | 12.21 Bn | 129.80 Bn |
| 4 | Novartis Ag | 303.14 Bn | 295.45 Bn | 11.24 Bn | 122.03 Bn |
| 5 | Astrazeneca | 257.68 Bn | 252.78 Bn | 12.86 Bn | 115.83 Bn |
| 6 | Amgen | 236.33 Bn | 222.34 Bn | 7.24 Bn | 95.64 Bn |
| 7 | Gilead Sciences | 182.14 Bn | 178.96 Bn | 6.22 Bn | 49.36 Bn |
| 8 | Pfizer | 159.30 Bn | 147.60 Bn | 10.94 Bn | 201.13 Bn |
| 9 | Gsk | 106.20 Bn | 102.03 Bn | 8.24 Bn | 82.83 Bn |
| 10 | Nasus Pharma | 31.64 Mn | 31.64 Mn | - | 5.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 5.00 Mn |
| Jun 30, 2025 | 639,000.00 |
| Dec 31, 2024 | 717,000.00 |